{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:24:34Z","timestamp":1783009474883,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.euros.2026.05.005","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:04:36Z","timestamp":1780412676000},"page":"56-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PSA Response as a Prognostic Marker in Metastatic Hormone-sensitive Prostate Cancer: Comparison with Tumor Volume (CHAARTED)"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4102-0820","authenticated-orcid":false,"given":"Roc\u00edo","family":"Mart\u00ednez-Corral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro De","family":"Pablos-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Ant\u00f3n-Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Bardella-Altarriba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"D\u00edaz-Pedrouzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaoqu\u00edn","family":"Abuin-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Vera-Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnau","family":"Abella-Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Elena","family":"Mart\u00ednez-Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"G\u00f3mez-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Picola-Brau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mart\u00ednez-Breijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Costa-Planells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"L\u00f3pez-Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Garc\u00eda-Puche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"P\u00e9rez-Fentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.05.005_b0005","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.05.005_b0010","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.05.005_b0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.05.005_b0020","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2026.05.005_b0025","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.05.005_b0030","unstructured":"Cornford P, Tilki D, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Limited update March 2025. Arnhem, The Netherlands: European Association of Urology; 2025."},{"key":"10.1016\/j.euros.2026.05.005_b0035","unstructured":"Schaeffer EM, Srinivas S, Adra N, et al. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): prostate cancer. version 1.2025. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2024."},{"key":"10.1016\/j.euros.2026.05.005_b0040","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.05.005_b0045","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/pros.70040","article-title":"Prostate-specific antigen response at six months predicts progression in metastatic hormone-sensitive prostate cancer treated with apalutamide","volume":"85","author":"Mart\u00ednez Osorio","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.euros.2026.05.005_b0050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","volume":"86","author":"Saad","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.05.005_b0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euros.2024.10.001","article-title":"Prostate-specific antigen at 3 months as a predictor of radiologic progression-free survival in metastatic hormone-sensitive prostate cancer treated with apalutamide: analysis of 633 patients in a real-world database","volume":"70","author":"Hassi Roman","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euros.2026.05.005_b0060","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/JU.0000000000004158","article-title":"Early prostate-specific antigen response by 6 months is predictive of treatment effect in metastatic hormone sensitive prostate cancer: an exploratory analysis of the Titan trial","volume":"212","author":"Roy","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.05.005_b0065","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.3390\/jcm13206221","article-title":"Ultralow prostate-specific antigen (PSA) levels and improved oncological outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with apalutamide: a real-world multicentre study","volume":"13","author":"L\u00f3pez-Abad","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.euros.2026.05.005_b0070","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in Titan patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2026.05.005_b0075","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.euo.2024.08.007","article-title":"Prostate-specific antigen nadir and cancer-control outcomes in real-world apalutamide-treated metastatic hormone-sensitive prostate cancer patients: a single-center analysis","volume":"8","author":"Wenzel","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2026.05.005_b0080","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/iju.15615","article-title":"Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the Titan trial: a post hoc analysis","volume":"32","author":"Ye","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.euros.2026.05.005_b0085","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.05.005_b0090","doi-asserted-by":"crossref","first-page":"124.e9","DOI":"10.1016\/j.urolonc.2025.10.012","article-title":"PSA response to predict progression in metastatic hormone-sensitive prostate cancer (mHSPC) patients. When is the optimal time point?","volume":"44","author":"Mart\u00ednez-Corral","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2026.05.005_b0095","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.05.005_b0100","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2026.05.005_b0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.8751","article-title":"Enzalutamide and prostate-specific antigen levels in metastatic prostate cancer: a secondary analysis of the ARCHES randomized clinical trial","volume":"8","author":"Azad","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euros.2026.05.005_b0110","article-title":"Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design","volume":"42","author":"Azad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.05.005_b0115","article-title":"EORTC GUCG 2238 \u201cde-escalate\u201d: a pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-na\u00efve prostate cancer in the era of new AR pathway inhibitors","volume":"42","author":"Guillaume","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.05.005_b0120","first-page":"574","article-title":"Prognostic model for overall survival in metastatic castration-resistant prostate cancer patients treated with first-line abiraterone or enzalutamide: development and validation","volume":"6","author":"Esen","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2026.05.005_b0125","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2026.05.005_b0130","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.eururo.2020.06.033","article-title":"Association of SPOP mutations with outcomes in men with de novo metastatic castration-sensitive prostate cancer","volume":"78","author":"Swami","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.05.005_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clgc.2019.09.015","article-title":"Androgen receptor splice variant, AR-V7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate cancer","volume":"18","author":"Zhang","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euros.2026.05.005_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107669","article-title":"Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress","volume":"31","author":"Nyquist","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.euros.2026.05.005_b0145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5129","article-title":"TRIPLE-SWITCH (SWOG\/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924)","volume":"43","author":"Ong","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326005033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326005033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:08:26Z","timestamp":1783008506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326005033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"alternative-id":["S2666168326005033"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.05.005","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSA Response as a Prognostic Marker in Metastatic Hormone-sensitive Prostate Cancer: Comparison with Tumor Volume (CHAARTED)","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}